These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30600148)

  • 1. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
    Liu X; Hu Y; Gao A; Xu M; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
    Bioorg Med Chem; 2019 Feb; 27(4):589-603. PubMed ID: 30600148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation.
    Hu Y; Gao A; Liao H; Zhang M; Xu G; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
    Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800039. PubMed ID: 30113716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
    Duan Z; Liu J; Niu L; Wang J; Feng M; Chen H; Luo C
    Bioorg Med Chem; 2019 Aug; 27(15):3229-3236. PubMed ID: 31208797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
    Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
    Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
    Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
    Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
    Jones S; Ahmet J; Ayton K; Ball M; Cockerill M; Fairweather E; Hamilton N; Harper P; Hitchin J; Jordan A; Levy C; Lopez R; McKenzie E; Packer M; Plant D; Simpson I; Simpson P; Sinclair I; Somervaille TC; Small H; Spencer GJ; Thomson G; Tonge M; Waddell I; Walsh J; Waszkowycz B; Wigglesworth M; Wiseman DH; Ogilvie D
    J Med Chem; 2016 Dec; 59(24):11120-11137. PubMed ID: 28002956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Chen Z; Wan H; Tang S; Ye Y; Xu Y; Jiang L; Ding J; Geng M; Huang M; Huang Y
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3808-3812. PubMed ID: 30413349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
    Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
    Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Insights for Inhibiting Mutant Heterodimer IDH1
    Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
    Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrative computational approach for the identification of dual inhibitors of isocitrate dehydrogenase 1 and 2 from phytocompounds of
    Bello RO; Okunlola ST; Kumar N; Victor O; Jimoh TO; Abdulsalam ZN; Kehinde IO; Umar HI
    J Biomol Struct Dyn; 2024 Sep; 42(14):7272-7288. PubMed ID: 37559488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 1: SAR of the aryl region.
    Levy DE; Wang DX; Lu Q; Chen Z; Perumattam J; Xu YJ; Liclican A; Higaki J; Dong H; Laney M; Mavunkel B; Dugar S
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2390-4. PubMed ID: 18334294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.
    Xu T; Yang J; Li D; Challa M; Zou C; Deng P; Zhang SL; Xu B
    Eur J Med Chem; 2024 Sep; 275():116610. PubMed ID: 38896992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
    Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
    Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.